Effective Strategies for Managing Sepsis and Liver Dysfunction in Patients

Clinical Characteristics of Sepsis and Liver Dysfunction Patients

Patients with sepsis and liver dysfunction often present with distinct clinical features that can guide diagnosis and treatment. In a recent study involving 95 patients diagnosed with sepsis, it was found that those with SALD had higher Sequential Organ Failure Assessment (SOFA) scores, indicating more severe illness compared to patients without liver dysfunction. The SOFA score is a widely used scoring system to determine the extent of a person’s organ function or rate of failure. The SOFA scores were significantly higher in the SALD group (median score of 8.00) compared to the non-SALD group (median score of 6.00), demonstrating the critical nature of liver involvement in sepsis (Table 1).

The study also indicated that the presence of jaundice, abdominal pain, and altered mental status were prevalent symptoms among patients with SALD, which can complicate the management of sepsis. Understanding these clinical characteristics is crucial for healthcare providers as they develop treatment protocols tailored to the specific needs of this patient population.

Laboratory Indicators: Key Tests for Sepsis and Liver Dysfunction

The diagnosis of sepsis and associated liver dysfunction is further supported by various laboratory indicators. In the aforementioned study, laboratory tests revealed significant differences between the SALD and non-SALD groups. For example, patients in the SALD group exhibited elevated white blood cell (WBC) counts and neutrophil levels, indicative of an inflammatory response. Furthermore, procalcitonin levels, a biomarker often used to diagnose bacterial infections, were also found to be significantly higher in the SALD group on day 3 of hospitalization.

The significant increase in fecal calprotectin levels in the SALD group compared to the non-SALD group indicates intestinal inflammation, which can correlate with poorer outcomes in patients with sepsis. Elevated fecal calprotectin levels (median of 520.00 μg/g in the SALD group) can serve as a valuable diagnostic marker for assessing the severity of liver dysfunction in septic patients (Table 2).

The correlation between elevated fecal calprotectin levels and poorer outcomes highlights the need for early intervention in septic patients with liver dysfunction. Monitoring these laboratory indicators can aid in timely decision-making regarding therapeutic strategies.

Treatment Approaches for Sepsis-Associated Liver Dysfunction

Management of SALD should be part of a comprehensive treatment strategy for sepsis. Initial treatment for sepsis includes the prompt administration of broad-spectrum antibiotics, intravenous fluids, and supportive care, with close monitoring of vital signs and laboratory parameters. In cases where liver dysfunction is present, additional measures may be required.

1. Fluid Resuscitation: Early fluid resuscitation is critical in patients with sepsis. Administering intravenous fluids can help restore hemodynamic stability and improve organ perfusion.

2. Antibiotic Therapy: Broad-spectrum antibiotics should be initiated as soon as possible to target the underlying infectious agents. The choice of antibiotic may be adjusted based on culture results and clinical response.

3. Monitoring and Support: Continuous monitoring of liver function tests, renal function, and hemodynamic status is essential. Supportive measures may include the use of vasopressors in cases of septic shock.

4. Nutritional Support: Early enteral nutrition is recommended for patients with sepsis to support metabolic needs and maintain gut integrity.

5. Use of Corticosteroids: In certain cases of severe sepsis or septic shock, low-dose corticosteroids may be administered to reduce inflammation and support adrenal function.

6. Management of Complications: Any acute complications, such as acute kidney injury or gastrointestinal bleeding, should be managed promptly.

7. Fecal Calprotectin Monitoring: Regular monitoring of fecal calprotectin levels can provide insights into gastrointestinal inflammation and help guide further management strategies.

Correlation Between Fecal Calprotectin and Patient Outcomes

Fecal calprotectin (FC) is a protein released by neutrophils and can serve as a biomarker for intestinal inflammation. Increased levels of FC have been associated with adverse outcomes in various gastrointestinal conditions, including inflammatory bowel disease and sepsis. The recent study indicated that the median FC levels significantly spiked in the SALD group, highlighting the role of intestinal inflammation in the management of sepsis.

Higher fecal calprotectin levels correlated with increased mortality rates, length of ICU stay, and severity of illness as measured by SOFA scores. These findings emphasize the importance of utilizing fecal calprotectin not only as a diagnostic tool but also as a prognostic indicator for clinical outcomes in septic patients.

Conclusion

The management of sepsis and liver dysfunction requires a multifaceted approach that includes clinical evaluation, laboratory monitoring, treatment of the underlying infection, and supportive care. Understanding the clinical characteristics, utilizing laboratory indicators, and recognizing the importance of fecal calprotectin can significantly improve patient outcomes in this critical patient population. Early diagnosis, timely intervention, and a collaborative approach among healthcare professionals are essential for effective management.

FAQ

What are the common symptoms of sepsis?
Common symptoms include fever, chills, rapid heart rate, confusion, shortness of breath, and severe discomfort or pain.

How is sepsis diagnosed?
Diagnosis typically involves clinical evaluation and laboratory tests, including blood cultures, complete blood count, and markers of organ dysfunction.

What is fecal calprotectin, and why is it important?
Fecal calprotectin is a biomarker for intestinal inflammation. Its levels can provide insights into gastrointestinal health and are associated with adverse outcomes in conditions like sepsis.

What treatment options are available for sepsis?
Treatment includes antibiotics, intravenous fluids, vasopressors for shock, and supportive care, with specific interventions based on patient needs.

How can I prevent sepsis?
Preventive measures include proper hygiene, vaccination, and timely treatment of infections.

References

1. Ramaswami, R., Kelesidis, T., & Goedert, J. J. (2025). When cytokine storms collide: understanding hemophagocytic lymphohistiocytosis in human herpesvirus 8/Kaposi sarcoma herpesvirus-associated multicentric Castleman disease among people with HIV. https://pubmed.ncbi.nlm.nih.gov/12065452/

2. Nasto, L. A., De Prisco, F., Pola, E., Perrotta, S., Miele, G., Piatelli, G., & Santoro, C. (2025). Severe cervical kyphosis in a complex child with NF1, case report and literature review. https://doi.org/10.1007/s00381-025-06831-3

3. Wang, G., Li, Z., Chen, L., Lugar, H., Hershey, T. (2025). Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models. https://doi.org/10.1371/journal.pone.0321598

4. Clinical characteristics of study participants. (2025). https://doi.org/10.7759/cureus.82004

5. Implementation of a novel patient reported experience measure (PREM) in rheumatology: a cross-sectional online survey of Australian rheumatology outpatients. (2025). https://doi.org/10.1007/s00296-025-05882-8